drugset / Trial / NCT05908526

Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes

NCT05908526

RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this study is to examine the impact of suvorexant, an FDA-approved insomnia medication, on daytime symptoms (as measured by the Daytime Insomnia Symptoms Scale: cognition, positive mood, negative mood, and fatigue/sleepiness) among older adults with insomnia. The primary hypothesis is that relative to placebo, suvorexant will improve sleep and daytime symptoms. The word "placebo" refers to a harmless pill with no therapeutic effect.

Timeline

Start
2023-10-09
Primary completion
2024-08-08
Completion
2024-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Suvorexant Small molecule 20 mg Oral

Indications